Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun;21(6):1259-69.
doi: 10.1038/mt.2013.65. Epub 2013 Apr 16.

Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases

Lijing Li  1 , Ludmila Krymskaya, Jianbin Wang, Jill Henley, Anitha Rao, Lan-Feng Cao, Chy-Anh Tran, Monica Torres-Coronado, Agnes Gardner, Nancy Gonzalez, Kenneth Kim, Pei-Qi Liu, Ursula Hofer, Evan Lopez, Philip D Gregory, Qing Liu, Michael C Holmes, Paula M Cannon, John A Zaia, David L DiGiusto
Affiliations

Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases

Lijing Li et al. Mol Ther. 2013 Jun.

Abstract

The HIV-1 coreceptor CCR5 is a validated target for HIV/AIDS therapy. The apparent elimination of HIV-1 in a patient treated with an allogeneic stem cell transplant homozygous for a naturally occurring CCR5 deletion mutation (CCR5(Δ32/Δ32)) supports the concept that a single dose of HIV-resistant hematopoietic stem cells can provide disease protection. Given the low frequency of naturally occurring CCR5(Δ32/Δ32) donors, we reasoned that engineered autologous CD34(+) hematopoietic stem/progenitor cells (HSPCs) could be used for AIDS therapy. We evaluated disruption of CCR5 gene expression in HSPCs isolated from granulocyte colony-stimulating factor (CSF)-mobilized adult blood using a recombinant adenoviral vector encoding a CCR5-specific pair of zinc finger nucleases (CCR5-ZFN). Our results demonstrate that CCR5-ZFN RNA and protein expression from the adenoviral vector is enhanced by pretreatment of HSPC with protein kinase C (PKC) activators resulting in >25% CCR5 gene disruption and that activation of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway is responsible for this activity. Importantly, using an optimized dose of PKC activator and adenoviral vector we could generate CCR5-modified HSPCs which engraft in a humanized mouse model (albeit at a reduced level) and support multilineage differentiation in vitro and in vivo. Together, these data establish the basis for improved approaches exploiting adenoviral vector delivery in the modification of HSPCs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Protein kinase C (PKC) activators (PMA and bryostatin) significantly enhanced CCR5-ZFN activity in CD34+ hematopoietic stem/progenitor cells (HSPC). Adult HSPCs were stimulated with SFT in SCGM medium overnight followed by PMA or bryostatin treatment for 30 minutes before CCR5-ZFN transduction (multiplicity of infection (MOI) 150). The percent CCR5 disruption was obtained by surveyor nuclease assay from transduced cells (MOI 150) without PKC activator treatment (left), with 20 ng/ml PMA treatment (middle), and 10 nmol/l bryostatin treatment (right). Percent of CCR5 disruption is indicated under each lane. PMA, phorbol 12-myristate 13-acetate; ZFN, zinc finger nuclease.
Figure 2
Figure 2
Effect of PMA and bryostatin treatment and vector transduction on hematopoietic stem/progenitor cell (HSPC) CD34+ cell growth and hematopoietic potential. (a) Colony-forming unit (CFU) assay. A total of 500 cells were plated in methylcellulose medium in triplicates for each condition and the average ± SD of CFU are shown. One way analysis of variance (ANOVA) with Dunnett's multiple comparison test was used for statistical analysis as compared with the untransduced control. *P < 0.05. (b) Growth of untransduced, PMA-, and bryostatin-treated, CCR5-ZFN–transduced cells cultured in bulk culture medium for 28 days. Average ± SD fold growth over starting cell number is shown, N = 3. (c) Phenotypic analysis of 2-week bulk culture and an one-way ANOVA performed with Bonferroni post-test. Error bars indicate average ± SEM of percent of total cells with each phenotype is shown, N = 3. ns, not significant; PMA, phorbol 12-myristate 13-acetate; Untd, untransduced; ZFN, zinc finger nuclease.
Figure 3
Figure 3
Protein kinase C activators induce phosphorylation of ERK1/2 in hematopoietic stem/progenitor cell (HSPC) CD34+ cells and result in enhancement of CCR5-ZFN activity. (a) CD34+ HSPCs from four healthy donors were stimulated with 1 ng/ml PMA and stained with anti-phospho-signal protein antibodies as indicated. Mean fluorescence intensity (MFI) of each phospho-signal protein was displayed. Two-way analysis of variance with Bonferroni post-test was used for statistical analysis, ***P < 0.001. (b) CD34+ HSPC from four donors were either untreated or treated in parallel with 1 ng/ml PMA or 5 nmol/l bryostatin. (c,d) CD34+ HSPCs from three donors were either mock-treated or treated with bryostatin (Bryo) and MEK1/2 inhibitor GSK1120212 (Bryo + 5 or 50 nmol/l GSK) at the concentration indicated 1 hour before bryostatin stimulation, followed by CCR5-ZFN vector transduction at multiplicity of infection 10 (all samples). (c) MFI of pERK and (d) % CCR5 disruption of the same samples as in c were measured. The relative fold change of the parameters listed was normalized to samples treated with bryostatin and vector only. Average ± SEM is shown for (c) pERK MFI and (d) CCR5 disruption. ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor-κB; PMA, phorbol 12-myristate 13-acetate; ZFN, zinc finger nuclease.
Figure 4
Figure 4
Protein kinase C (PKC) activation increases CCR5-ZFN RNA expression leading to enhanced protein production. (a) Reverse transcription-PCR analysis of CCR5-ZFN mRNA using CCR5-ZFN-Fok1 endonuclease-specific primers. Untreated, CCR5-ZFN transduced (multiplicity of infection (MOI) 50) without PMA treatment (0PMA-50), and 1 ng/ml PMA-treated and CCR5-ZFN–transduced (1PMA-50) CD34+ cells from five donors were analyzed. (b) Western blot analysis of Fok1 endonuclease protein expression in hematopoietic stem/progenitor cells treated with PKC activators at the concentrations indicated and transduced with CCR5-ZFN vector (MOI 50). (c) Dose-dependent inhibition of the Fok1 endonuclease protein by MEK inhibitor GSK1120212 at indicated concentrations before bryostatin treatment (5 nmol/l) and CCR5-ZFN transduction (MOI 50). PMA, phorbol 12-myristate 13-acetate; ZFN, zinc finger nuclease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, HIV Incidence Surveillance Group et al. Estimated HIV incidence in the United States, 2006-2009. PLoS ONE. 2011;6:e17502. - PMC - PubMed
    1. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360:692–698. - PubMed
    1. Allers K, Hütter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. Evidence for the cure of HIV infection by CCR5?32/?32 stem cell transplantation. Blood. 2011;117:2791–2799. - PubMed
    1. Baltimore D. Gene therapy. Intracellular immunization. Nature. 1988;335:395–396. - PubMed
    1. Hoxie JA, June CH. Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med. 2012;2:pii: a007179. - PMC - PubMed

Publication types

MeSH terms